Danazol
Danocrine (danazol) is a small molecule pharmaceutical. Danazol was first approved as Danocrine on 1982-01-01. It is used to treat endometriosis and fibrocystic breast disease in the USA. The pharmaceutical is active against androgen receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| urogenital diseases | D000091642 |
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Danazol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DANOCRINE | Sanofi | N-017557 DISCN | 1982-01-01 | 3 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| danazol | ANDA | 2023-03-03 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| endometriosis | EFO_0001065 | D004715 | N80 |
| fibrocystic breast disease | — | D005348 | N60 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| G9507 | Documentation that the patient is on a statin medication or has documentation of a valid contraindication or exception to statin medications; contraindications/exceptions that can be defined by diagnosis codes include pregnancy during the measurement period, active liver disease, rhabdomyolysis, end stage renal disease on dialysis and heart failure; provider documented contraindications/exceptions include breastfeeding during the measurement period, woman of child-bearing age not actively taking birth control, allergy to statin, drug interaction (hiv protease inhibitors, nefazodone, cyclosporine, gemfibrozil, and danazol) and intolerance (with supporting documentation of trying a statin at least once within the last 5 years or diagnosis codes for myostitis or toxic myopathy related to drugs) |
Clinical
Clinical Trials
162 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | 12 | 34 | 20 | 1 | 1 | 62 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hodgkin disease | D006689 | C81 | 3 | 23 | 11 | — | 1 | 36 | |
| Lymphoma | D008223 | C85.9 | — | 9 | 8 | — | 1 | 18 | |
| Sarcoma | D012509 | 3 | 8 | 3 | — | 1 | 13 | ||
| Leiomyosarcoma | D007890 | 1 | 3 | 4 | — | — | 7 | ||
| Uveal neoplasms | D014604 | EFO_1001230 | — | 5 | 1 | — | — | 6 | |
| Neuroblastoma | D009447 | EFO_0000621 | — | 1 | 3 | — | 1 | 5 | |
| Neoplasms | D009369 | C80 | 2 | 2 | 1 | — | — | 4 | |
| Synovial sarcoma | D013584 | — | 1 | 1 | — | — | 2 | ||
| Skin neoplasms | D012878 | EFO_0004198 | C44 | — | — | 1 | — | — | 1 |
| Alveolar soft part sarcoma | D018234 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 3 | — | — | — | 3 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | — | 2 | — | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 2 | — | — | — | 2 | |
| Thyroid neoplasms | D013964 | EFO_0003841 | 1 | 1 | — | — | — | 1 | |
| T-cell lymphoma peripheral | D016411 | C84.9 | — | 1 | — | — | — | 1 | |
| Solitary fibrous tumors | D054364 | — | 1 | — | — | — | 1 | ||
| Immunotherapy | D007167 | — | 1 | — | — | — | 1 | ||
| Neurofibrosarcoma | D018319 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Small cell lung carcinoma | D055752 | 1 | — | — | — | — | 1 | ||
| Carcinoid tumor | D002276 | D3A.00 | 1 | — | — | — | — | 1 | |
| Parathyroid neoplasms | D010282 | 1 | — | — | — | — | 1 | ||
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | — | — | — | — | 1 |
| Lung neoplasms | D008175 | C34.90 | 1 | — | — | — | — | 1 | |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 1 | — | — | — | — | 1 |
| Colonic neoplasms | D003110 | C18 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DANAZOL |
| INN | danazol |
| Description | Danazol is a 17beta-hydroxy steroid and a terminal acetylenic compound. It has a role as an anti-estrogen, an estrogen antagonist and a geroprotector. It derives from a hydride of a pregnane. |
| Classification | Small molecule |
| Drug class | Androgen; Anabolic steroid; Progestogen; Progestin; Antigonadotropin; Steroidogenesis inhibitor; Antiestrogen |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 17230-88-5 |
| RxCUI | 3102 |
| ChEMBL ID | CHEMBL1479 |
| ChEBI ID | 4315 |
| PubChem CID | 28417 |
| DrugBank | DB01406 |
| UNII ID | N29QWW3BUO (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,946 documents
View more details
Safety
Black-box Warning
Black-box warning for: Danazol
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
4,676 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more